Pulmonary Arterial Hypertension (PAH) Treatment Market Size, Share and Global Trend By Drug Class (Soluble Guanylate Cyclase (SGC) Stimulators,Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA)), By End User (Hospitals, Clinics, Others), and Regional Forecast, 2024-2032

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease defined by increasing pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to heart failure. Symptoms of pulmonary arterial hypertension (PAH) include shortness of breath (dyspnea) during exercise, chest pain, and fainting episodes. The exact cause of pulmonary arterial hypertension (PAH) is unknown and although treatable, there is no known cure for this disease.

PAH usually affects women between the ages of 30-60. According to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), the new cases are estimated to occur in one to two individuals per million each year in the U.S.

The increasing prevalence of pulmonary arterial hypertension (PAH) due to causative diseases including lung diseases, human immunodeficiency virus (HIV) infection, connective tissue disorders, chronic liver diseases, and other conditions are some of the factors driving the growth of the global pulmonary arterial hypertension (PAH) market. Additionally, increasing adoption of the sedentary lifestyle, rising consumption of alcohol, and increased smoking prevalence among adults are factors presenting a large patient pool suffering from pulmonary arterial hypertension globally. 

However, the high cost of the treatment of pulmonary arterial hypertension is a major factor restraining the growth of the global pulmonary arterial hypertension (PAH) treatment market.

Key Players Covered

Some of the major companies that are present in the global pulmonary arterial hypertension (PAH) treatment market are Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Bayer AG, United Therapeutics Corp, and others.

SEGMENTATION

In 2018, among drug class, prostacyclin and prostacyclin analogs dominated the global pulmonary arterial hypertension (PAH) treatment market owing to the development in oral prostacyclin agents, leading to the introduction of more efficient drugs such as Orenitram and Uptravi. This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights

• Prvalance of Pulmonary Arterial Hypertension (PAH) Key Countries/Region


• Pipeline Analysis, Key Players


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

North America accounted for the largest market share of the global pulmonary arterial hypertension (PAH) treatment market in 2018. Rising prevalence of cardiovascular diseases combined with the increasing number of regulatory approvals being granted to new treatment medications are some of the factors driving the growth of the pulmonary arterial hypertension (PAH) treatment market in North America. Additionally, supportive legislation like the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. aided the development of novel medication for pulmonary arterial hypertension in the region.

Key Industry Developments

• In May 2019, Teva Pharmaceutical Industries Ltd., launched generic version of Gilead’s Letairis (ambrisentan) tablets in the United States. Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH).
• In Sepember 2017, Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, received U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for TRACLEER (bosentan) for use in pediatric patients aged three years and older with idiopathic or congenital pulmonary arterial hypertension (PAH).